FibroGen, Inc. is a United States-based pharmaceutical company specializing in developing novel therapeutics for treating cancer biology and anemia. With an ESG score of 28.1, the company is rated as a medium-risk investment. FibroGen focuses on partnering with other organizations to advance product candidates and generates revenue primarily from collaboration agreements. The company's operations are centered around addressing serious unmet medical needs in Europe and Japan.